Department of Cardiovascular Medicine Nara Medical University Kashihara Japan.
Department of Cardiology Saiseikai Suita Hospital Suita Japan.
J Am Heart Assoc. 2020 Aug 18;9(16):e015593. doi: 10.1161/JAHA.119.015593. Epub 2020 Aug 1.
BACKGROUND Vascular healing response associated with adjunctive n-3 polyunsaturated fatty acid therapy therapy in patients receiving strong statin therapy remains unclear. The aim of this study was to evaluate the effect of polyunsaturated fatty acid therapy with eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) in addition to strong statin therapy on coronary atherosclerotic plaques using optical coherence tomography. METHODS AND RESULTS This prospective multicenter randomized controlled trial included 130 patients with acute coronary syndrome treated with strong statins. They were assigned to either statin only (control group, n=42), statin+high-dose EPA (1800 mg/day) (EPA group, n=40), statin+EPA (930 mg/day)+DHA (750 mg/day) (EPA+DHA group, n=48). Optical coherence tomography was performed at baseline and at the 8-month follow-up. The target for optical coherence tomography analysis was a nonculprit lesion with a lipid plaque. Between baseline and the 8-month follow-up, fibrous cap thickness (FCT) significantly increased in all 3 groups. There were no significant differences in the percent change for minimum FCT between the EPA or EPA+DHA group and the control group. In patients with FCT <120 µm (median value), the percent change for minimum FCT was significantly higher in the EPA or EPA+DHA group compared with the control group. CONCLUSIONS EPA or EPA+DHA therapy in addition to strong statin therapy did not significantly increase FCT in nonculprit plaques compared with strong statin therapy alone, but significantly increased FCT in patients with thinner FCT. Registration URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN 000012825.
在接受强他汀治疗的患者中,联合应用 n-3 多不饱和脂肪酸治疗与血管愈合反应的关系尚不清楚。本研究旨在使用光学相干断层扫描评估在强他汀治疗基础上加用二十碳五烯酸(EPA)或二十二碳六烯酸(DHA)的多不饱和脂肪酸治疗对冠状动脉粥样硬化斑块的影响。
这项前瞻性多中心随机对照试验纳入了 130 名接受强他汀治疗的急性冠状动脉综合征患者。他们被分为仅用他汀(对照组,n=42)、他汀+高剂量 EPA(1800mg/天)(EPA 组,n=40)、他汀+EPA(930mg/天)+DHA(750mg/天)(EPA+DHA 组,n=48)。基线和 8 个月随访时进行光学相干断层扫描。光学相干断层扫描分析的目标是非罪犯病变伴脂质斑块。与基线相比,所有 3 组的纤维帽厚度(FCT)均显著增加。在 EPA 或 EPA+DHA 组与对照组之间,最小 FCT 的百分比变化无显著差异。在 FCT<120µm(中位数)的患者中,与对照组相比,EPA 或 EPA+DHA 组的最小 FCT 百分比变化显著更高。
与单独使用强他汀治疗相比,在强他汀治疗的基础上加用 EPA 或 EPA+DHA 治疗并未显著增加非罪犯斑块的 FCT,但在 FCT 较薄的患者中,FCT 显著增加。
https://www.umin.ac.jp/ctr/;唯一识别码:UMIN 000012825。